Navigation Links
Engineered immune cells produce complete response in child with an aggressive pediatric leukemia
Date:12/9/2012

By reprogramming a 7-year-old girl's own immune cells to attack an aggressive form of childhood leukemia, a pediatric oncologist has achieved a complete response in his patient, who faced grim prospects when she relapsed after conventional treatment. The innovative experimental therapy used bioengineered T cells, custom-designed to multiply rapidly in the patient, and then destroy leukemia cells. After the treatment, the child's doctors found that she had no evidence of cancer.

Pediatric oncologist Stephan A. Grupp, M.D., Ph.D., of The Children's Hospital of Philadelphia, and colleagues from the University of Pennsylvania presented updated results of the clinical trial involving these engineered cells at the American Society of Hematology (ASH) annual meeting today in Atlanta. Grupp is the director of Translational Research for the Center for Childhood Cancer Research at The Children's Hospital of Philadelphia, and a professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.

Grupp's research builds on his ongoing collaboration with Penn scientists who originally developed the modified T cells as a treatment for B-cell leukemias. The Penn team reported on early results of a trial using this cell therapy in adult chronic lymphocytic leukemia (CLL) patients in August of 2011. Carl H. June, M.D., of the Perelman School of Medicine at the University of Pennsylvania, leads this research group, which along with Grupp's work, is presenting new data at the ASH meeting showing that nine of 12 patients with advanced leukemias in the clinical trial, including two children, responded to treatment with CTL019 cells.

One of the nine responding patients is the 7-year-old with acute lymphoblastic leukemia (ALL). Grupp and Penn colleagues adapted the treatment to combat ALL, the most common childhood leukemia, and also the most common childhood cancer. Although physicians can cure roughly 85 percent of ALL cases, the
'/>"/>

Contact: Rachel Salis-Silverman
Salis@email.chop.edu
267-970-3685
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Leukemia patients remain in remission more than 2 years after engineered T cell therapy
2. Bioengineered marine algae expands environments where biofuels can be produced
3. Soft Robotics: A groundbreaking new journal on engineered soft devices that Interact with Living Systems
4. Engineered bacteria can make the ultimate sacrifice
5. Ecologist: Genetically engineered algae for biofuel pose potential risks that should be studied
6. Success of engineered tissue depends on where its grown
7. Lab-engineered kidney project reaches early milestone
8. Engineered robot interacts with live fish
9. Engineered microvessels provide a 3-D test bed for human diseases
10. New research reveals challenges in genetically engineered crop regulatory process
11. Ultrasound idea: Prototype NIST/CU bioreactor evaluates engineered tissue while creating it
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... PAUL, Minn. , Dec. 10, 2014 /PRNewswire/ ... wireless physiologic monitoring, has released a new series ... needs of preclinical toxicology researchers. M series, part ... help toxicologists collect the best possible physiologic data ... Adding functional endpoints to toxicology studies ...
(Date:12/10/2014)...  Wake Forest Baptist Medical Center today announced plans for ... Medicine. Funding for this $50 million capital project is ... publicly launched next summer. The medical ... series R.J. Reynolds Tobacco Company complex, adjacent to 525@vine ... with plans to be ready to welcome medical students ...
(Date:12/10/2014)... , December 9, 2014 ... ITN,s BCARD Platform   ... enterprise meeting scheduling solutions for business-to-business (B2B) events, ... world leader in mobile near-field communication (NFC), Bluetooth ...      (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... by University of Toronto Scarborough researchers gives the best ... severe mental illness called Borderline Personality Disorder (BPD), and ... work shows that brain regions that process negative emotions ... with BPD, while brain regions that would normally help ...
... since the early 1960s have fueled a sharp increase in ... consumed by the average person over the course of a ... McGill University. Between 1961 and 2007, rising meat consumption ... world,s per capita "phosphorus footprint," the researchers conclude in a ...
... organisms. They are still present today in oceans and ... and evolving into multicellular forms, they played a key ... This has, now, been demonstrated by a team of ... from the University of Zurich. According to their studies, ...
Cached Biology News:New insights into the 'borderline personality' brain 2Dietary shifts driving up phosphorus use 2Pediatric coding top tips and pediatric CPT changes 2013 2
(Date:12/22/2014)... 22, 2014 The Center for ... of technical training across the life sciences industry, has ... (SCDM) to provide the organization's members with discounted ... access to the more than 350 sessions across 80 ... 10% off when registering for a public course ...
(Date:12/22/2014)... 22, 2014 /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: ... focused on the development of autologous cell therapies, announced ... University of Calgary in conjunction with co-authors from Kyoto ... validates the company,s ongoing clinical research using dermal sheath ... baldness. The paper entitled " Hair Follicle ...
(Date:12/22/2014)... 2014 GenomeDx Biosciences today announced that a ... a genomic test for prostate cancer, was able to ... by radical prostatectomy without adjuvant therapy. Although rapid metastasis ... using tumor genomics to identify these men who have ... important advance. The study has been published online ...
(Date:12/22/2014)... 22, 2014 The American ... of original research, reviews and editorials addressing developments ... practice, today published a provocative article exploring the ... progression and potential treatment of prostate cancer. ... and proposes the possibility that there could be ...
Breaking Biology Technology:CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 2Study Published in European Urology Shows that the Decipher Prostate Cancer Classifier is Predictive of Rapid Metastasis in High-Risk Men who have had Prostate Surgery 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... over 60% of evaluable patients -, SEOUL, South ... today reported interim data from an ongoing phase 2 ... cell,lung cancer (NSCLC). This open-label phase 2 trial is ... NSCLC who have adenocarcinoma,histology and meet one of the ...
... Computing researchers at Houston,s Rice University and ... today announced the formation of a $2.6-million Institute ... valued at 4 million Singapore dollars, aims to ... microchips -- special-purpose computer chips that power everything ...
... Beckman Coulter,Inc. (NYSE: BEC ), a ... automate, and innovate complex biomedical testing,announced today that ... will present at the 2007 Bear Stearns Healthcare,Conference ... (EDT). (Logo: http://www.newscom.com/cgi-bin/prnh/20031202/BECLOGO ) The ...
Cached Biology Technology:Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 2Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 3Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer 4Rice, Nanyang Tech collaborate on sustainable nanoelectronics 2Rice, Nanyang Tech collaborate on sustainable nanoelectronics 3Beckman Coulter to Present at the Bear Stearns Healthcare Conference 2
Request Info...
Request Info...
CoverWell imaging chamber gasket with adhesive, one chamber, 20 mm diameter, 1.0 mm deep *set of 40* Cell Biology Imaging Tools and Accessories Microscope Slide Accessories...
Request Info...
Biology Products: